---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-002344"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:14:49.163460+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MoonLake gets FDA clarity on SLK in HS; no new trials needed for BLA submission

## Summary
- FDA confirms MoonLake can establish substantial evidence of effectiveness using existing VELA-1, VELA-2, and MIRA trials; no additional HS trials required.
- BLA submission for Sonelokimab in HS on track for H2 2026; Investor Day set for Feb 23, 2026 to discuss FDA feedback and new data.
- FDA advised including VELA-2 results in BLA to inform safety profile, regardless of role in establishing effectiveness.
- Upcoming milestones: Phase 2 S-OLARIS (axSpA) Q1 2026; Phase 3 IZAR-1 (PsA) mid-2026; VELA-TEEN adolescent HS readout mid-2026.

## SEC filing metadata
- accession: 0001213900-26-002344
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390026002344/0001213900-26-002344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390026002344/ea0272252-8k_moonlake.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-002344
- JSON: https://secwatch.observer/filing/0001213900-26-002344.json
- Plain text: https://secwatch.observer/filing/0001213900-26-002344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.